EPRX Stock Overview
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Eupraxia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.60 |
| 52 Week High | CA$9.10 |
| 52 Week Low | CA$3.60 |
| Beta | 1.13 |
| 1 Month Change | -20.88% |
| 3 Month Change | -31.17% |
| 1 Year Change | -34.07% |
| 3 Year Change | -39.50% |
| 5 Year Change | n/a |
| Change since IPO | -47.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| EPRX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -6.5% | -6.4% | -2.1% |
| 1Y | -34.1% | -35.6% | 3.6% |
Return vs Industry: EPRX matched the Canadian Biotechs industry which returned -33.7% over the past year.
Return vs Market: EPRX underperformed the Canadian Market which returned 3.2% over the past year.
Price Volatility
| EPRX volatility | |
|---|---|
| EPRX Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: EPRX's share price has been volatile over the past 3 months.
Volatility Over Time: EPRX's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 29 | James Helliwell | www.eupraxiapharma.com |
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain.
Eupraxia Pharmaceuticals Inc. Fundamentals Summary
| EPRX fundamental statistics | |
|---|---|
| Market cap | CA$130.02m |
| Earnings (TTM) | -CA$38.96m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs EPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$28.22m |
| Earnings | -US$28.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1,165.3% |
How did EPRX perform over the long term?
See historical performance and comparison